Reference : Personalising metformin therapy: a clinician's perspective
Scientific journals : Short communication
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
Personalising metformin therapy: a clinician's perspective
SCHEEN, André mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Lancet Diabetes and Endocrinology
Yes (verified by ORBi)
[en] If lifestyle changes are not effective for maintaining glycaemic control, metformin is recommended as the first glucose-lowering drug to use in a patient with type 2 diabetes, if the patient has no contraindications—eg, renal impairment or hypoxic disorders.1 However, the glucose-lowering response to metformin can vary greatly between patients, with some people responding poorly to this biguanide. Because of the well known therapeutic inertia with respect to pharmacological treatment of diabetes, insufficient glucose control might persist for a long time before any treatment adjustment is made in people who respond poorly to metformin monotherapy.
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Open access
TXT Comment Metformin genetics Lancet Diabetes Endocrinol Final 2014.pdfAuthor postprint177.42 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.